Angelini Pharma Announces $4.1 Billion Acquisition of Catalyst Pharmaceuticals to Enter US Rare Disease Market
核心洞察
Angelini Pharma (搜索) has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion ($31.50 per share), representing a 28% premium to the 30-day volume-weighted average trading price.
The transaction marks Angelini Pharma (搜索)'s strategic entry into the US market and strengthens its focus on rare neurological diseases through Catalyst's portfolio of FDA-approved treatments.
Catalyst's key products include FIRDAPSE for Lambert-Eaton myasthenic syndrome (搜索), AGAMREE for Duchenne muscular dystrophy (搜索), and FYCOMPA for epilepsy (搜索).
Italian pharmaceutical company Angelini Pharma (搜索) has entered into a definitive agreement to acquire Catalyst Pharmaceuticals for approximately $4.1 billion, marking a significant expansion into the US rare disease market. The all-cash transaction, valued at $31.50 per share, represents a 21% premium to Catalyst's closing share price on April 22, 2026, and a 28% premium to the 30-day volume-weighted average trading price.
The acquisition has received unanimous approval from both companies' boards of directors and is expected to close in the third quarter of 2026. The transaction will be financed with participation from Blackstone (搜索) funds and select international partners, with BNP Paribas (搜索) serving as Sole Global Coordinator and Underwriter.
Strategic Entry into US Market
This acquisition represents a pivotal moment for Angelini Pharma (搜索), a company with over 100 years of history that is part of the Angelini Industries Group. The deal establishes the Italian pharmaceutical company's presence in the US market while reinforcing its commitment to Brain Health and rare diseases.
"Five years ago, we embarked on a profound transformation of Angelini Pharma (搜索) — organizational, scientific and strategic — with the ambition to build a company capable of competing at the highest global level," said Sergio Marullo di Condojanni, CEO of Angelini Pharma. "Today, we take another significant step with the acquisition of Catalyst Pharmaceuticals, which we believe will establish Angelini Pharma as a relevant global player in neurological Rare Diseases."
Catalyst's Rare Disease Portfolio
Founded in 2002 and listed on Nasdaq since 2006, Catalyst has developed a robust portfolio focused on rare neuromuscular and neurological diseases. The company's key products include:
FIRDAPSE® (amifampridine): The only evidence-based treatment approved by the FDA for Lambert-Eaton myasthenic syndrome (搜索) (LEMS) in patients aged six and above.
AGAMREE® (vamorolone): A novel corticosteroid approved by the FDA in 2023 for treating Duchenne Muscular Dystrophy (搜索) (DMD) in patients aged 2 and above.
FYCOMPA® (perampanel): An antiepileptic drug for partial-onset seizures and primary generalised tonic-clonic seizures, with US rights acquired from Eisai in 2023.
Financial Performance and Market Position
Catalyst's market performance has been strong, with shares rising 24% over the past 12 months, bringing the company's market capitalization to approximately $3.6 billion. The company has established itself as a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for patients with rare and difficult-to-treat diseases.
Angelini Pharma (搜索) has demonstrated solid financial performance, recording revenues of EUR 1,207.3 million in 2024, representing a 3.6% increase compared to the previous year. More than half of these revenues (50.6%) came from international markets. The company's EBITDA increased to EUR 302.4 million with an EBITDA margin of 25%, up from 22.8% in 2023.
Integration and Future Strategy
Following completion of the acquisition, Angelini Pharma (搜索) plans to integrate Catalyst's portfolio and commercial infrastructure with its own expertise in Brain Health to develop a next-generation therapeutic platform in rare diseases. The transaction supports Angelini Pharma's balanced strategy to develop the North American market while continuing to strengthen its core business in Europe.
"By combining our unique capabilities in rare diseases with Angelini's proven global reach, we will create a stronger, scalable, and robust rare disease platform to expand access to life-changing therapies worldwide," commented Rich Daly, President and CEO of Catalyst.
The combined company will maintain Angelini Pharma (搜索)'s industrial presence in Italy as a strategic production and scientific center within the global operations. Angelini Pharma operates directly in 20 countries and markets its products in 70 countries across Europe, North America, South America, and Asia, employing more than 2,800 people worldwide.
The company's commitment to research and development continues to grow, with R&D investments reaching EUR 62 million in 2024, supporting its focus on Brain Health, including Mental Health and Epilepsy (搜索), Specialty and Primary Care, and Consumer Healthcare.